IMS 2025 | Updates on myeloma research from IMS 2025: advances in frontline and R/R treatment

We are here from IMS 2025 in Toronto. This was an amazing conference. We are going to see that the diagnostic and therapeutic revolution in multiple myeloma is going to continue. Starting from the revolution in frontline setting where we have a new potential backbone isatuximab new generation anti-CD38 monoclonal antibody. We have discussed in a brilliant symposium in plenary session about the use in both transplant eligible with the GMMG clinical trial and transplant ineligible with the IMROZ clinical trial in combination with the VRd. We are ambitious about the changing of end point. MRD negativity will became our aim and this will be feasable also thanks to the possibility to use this combinations also in elderly repopulation also not properly fit because this drug have a very good tolerability. And OBI presented in both IRAKLIA and IZALCO has shown that through a tool on body injection we can administrate this in a fast and safe way also in a domestic setting as we have seen in a sub analysis presented here in Toronto. Starting from frontline setting we have to say that new opportunities are arriving integrating imunotherapies of new generation also for these patients. We have seen that elranatamab is going to be explored also frontline setting the bispecific antibody anti-BCMA/CD3. And we are going to see also new combination in the relapsed/refractory setting where we are going to see a new revolution with the integration of both CAR-T and bispecific antibodies. And the new challenge will be to understand how to position this drug which is the correct sequencing to personalize the treatment and I think that the analysis about new molecular evaluation about circulating plasma cells and many other tools that are going to evaluate how to personalize the treatment will improve us to understand which is the right drug or combination for every patients. Let’s not forget that relapsed/refractory setting is not done only of these imunotherapies but new CAR-T constructs are arriving active on new targets so we can develop a new potential imunotherapy-driven approach also in later lines of treatment. And we have some drugs that are going to be integrated in our daily world. We wait for more solid data from CELMoDs. I’m particularly curious about the success of mezigdomide, carfilzomib, dexamethasone data. Let’s not forget totally new mechanism of action such as inobrodib. And let’s not forget that in sometime we need bridge to treatment and I think that selinexor data in preserving T-cell function is something that we can use as bridge to new immune therapies in every patients. We are going to explore a new combination also sometime a challenge of the previously used the drug and that’s why we can in some way imagine a potential long-term sequencing. Let’s not forget that we have also new way of performing a chemotherapy such as melflufen that can be used in a simple way also for really every treated elderly patient thanks to a mono administration monthly and thanks to a wonderful tolerability. All these drugs, all these combinations are going to be positioned in the correct way. Let’s not forget that we are going also to anticipate the treatment to prevent multiple myeloma and also here we have spoken a lot about the idea of how is intended high risk smoldering myeloma and which patient is better to anticipate the treatment and many drugs are arrived. AQUILA has confirmed the registration the evaluation for daratumumab in monotherapy but also combinations that are arriving. We will see in my opinion exciting data from MITAKA isatuximab, lenalidomide, dexamethasone. And also from bispecific antibodies. We have just completed the enrollment with the EMN34 elranatamab this setting of patients. All these drugs, all these tools to tell that the cure of multiple myeloma is not so far and this is the best wish that I give to our patient, to their caregivers and to all myeloma researchers.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.